Table of Contents

1.       Research Methodology

2.       Project Scope & Definitions

3.       Impact of Covid-19 on Japan Cancer Drug Market

4.       Executive Summary

5.       Japan Cancer Drug Market Outlook, FY2017-FY2031F

5.1.    Market Size & Forecast

5.1.1.By Value

5.1.2.By Volume

5.2.    By Application                                    

5.2.1. Lung Cancer

5.2.2.Blood Cancer

5.2.3.Colorectal Cancer

5.2.4.Prostate Cancer

5.2.5.Breast Cancer

5.2.6.Cervical Cancer

5.2.7.Glioblastoma

5.2.8.Head & Neck Cancer

5.2.9.Malignant Meningioma

5.2.10.  Mesothelioma

5.2.11.  Melanoma

5.2.12.  Others

5.3.    By Therapeutics

5.3.1.Chemotherapy

5.3.2.Targeted Therapy

5.3.3.Immunotherapy

5.3.4.Hormonal Therapy

5.3.5.Other

5.4.    By Top Selling Drugs

5.4.1.Revlimid

5.4.2.Avastin

5.4.3.Herceptin

5.4.4.Rituxan

5.4.5.Opdivo

5.4.6.Gleevec

5.4.7.Velcade

5.4.8.Imbruvica

5.4.9.Ibrance

5.4.10.    Zytiga

5.4.11.    Alimta

5.4.12.    Xtandi

5.4.13.    Tarceva

5.4.14.    Perjeta

5.4.15.    Temodar

5.4.16.    Others

2.1. By End-user

2.1.1.   Hospitals

2.1.2.   Specialty Clinics

2.1.3.   Cancer & Radiation Therapy

2.2. By Region

2.2.1.       North [Hokkaido and Tohoku]

2.2.2.       Central [Kanto and Chubu]

2.2.3.       South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]

2.3. By Company Market Share (%), FY2023

6.       Market Mapping, FY2023

6.1. By Application

6.2. By Therapeutics

6.3. By Top Selling Drugs

6.4. By End-user

6.5. By Region

7.       Macro Environment and Industry Structure

7.1. Supply Demand Analysis

7.2. Import Export Analysis

7.3. Value Chain Analysis

7.4. PESTEL Analysis

7.4.1.       Political Factors

7.4.2.       Economic System

7.4.3.       Social Implications

7.4.4.       Technological Advancements

7.4.5.       Environmental Impacts

7.4.6.       Legal Compliances and Regulatory Policies (Statutory Bodies Included)

7.5. Porter’s Five Forces Analysis

7.5.1.       Supplier Power

7.5.2.       Buyer Power

7.5.3.       Substitution Threat

7.5.4.       Threat from New Entrant

7.5.5.       Competitive Rivalry

8.       Market Dynamics

8.1. Growth Drivers

8.2. Growth Inhibitors (Challenges and Restraints)

9.       Regulatory Framework and Innovation

9.1. Clinical Trials

9.2. Patent Landscape

9.3. Regulatory Approvals

9.4. Innovations/Emerging Technologies

10.   Key Players Landscape

10.1.  Competition Matrix of Top Five Market Leaders

10.2.  Market Revenue Analysis of Top Five Market Leaders (in %, FY2023)

10.3.  Mergers and Acquisitions/Joint Ventures (If Applicable)

10.4.  SWOT Analysis (For Five Market Players)

10.5.  Patent Analysis (If Applicable)

11.   Pricing Analysis

12.   Case Studies

13.   Key Players Outlook

13.1.  Daiichi Sankyo Company, Ltd.

13.1.1.    Company Details

13.1.2.    Key Management Personnel

13.1.3.    Products & Services

13.1.4.    Financials (As reported)

13.1.5.    Key Market Focus & Geographical Presence

13.1.6.    Recent Developments

13.2.         Takeda Pharmaceutical Company Ltd.

13.3.         Chugai Pharmaceutical Co., Ltd.

13.4.         Astellas Pharma Inc.

13.5.         Otsuka Pharmaceutical Co., Ltd.

13.6.         Eisai Co., Ltd.

13.7.         Shionogi & Co., Ltd.

13.8.         Kyowa Kirin Co., Ltd.

13.9.         Ono Pharmaceutical Co., Ltd.

13.10.     Sumitomo Pharma Co., Ltd.

13.11.     Novartis Pharma K.K.

13.12.     Bristol-Myers Squibb Company Ltd.

13.13.     Janssen Pharmaceutical K.K

13.14.     AstraZeneca Pharma Japan Ltd.

13.15.     Pfizer Japan Inc.

14.   Strategic Recommendations

15.   About Us & Disclaimer